Essential thrombocythemia (ET) is a chronic myeloproliferative disorder, characterized by increased proliferation of megakaryocytes and elevated platelet count that usually occurs sporadically. We report a family with seven affected individuals in three generations, including one individual with a phenotype resembling polycythemia vera, a related disorder. Megakaryocyte (CFU-MK) colony formation occurred in the absence of added cytokines in cultures of peripheral blood from affected family members. Some reports of familial ET have identified mutations in THPO and MPL, the genes for a cytokine (thrombopoietin, TPO) that regulates platelet production and its receptor (c-MPL), respectively. In this family, the MPL gene was excluded by linkage analysis. Although TPO levels were elevated in most affected family members and evidence for linkage was found between the disease and THPO (h ¼ 0.0, Z max ¼ 3.0), a THPO mutation was not identified by DNA sequencing. The JAK2 V617F mutation that has been associated with 50% of sporadic cases of ET was identified as a somatic mutation, an acquired defect, in peripheral blood of the two most severely affected family members. These patients also had elevated TPO levels. Further study of familial myeloproliferative diseases will help elucidate the initiating genetic events underlying ET.
Introduction
Essential thrombocytemia (ET) is a chronic myeloproliferative disorder (MPD) characterized by megakaryocytic hyperplasia, elevated platelet count, abnormal platelets, thrombotic episodes and recurrent bleeding. 1 ET can evolve into an aggressive secondary acute myeloid leukemia. [1] [2] [3] The malignant nature of ET is evident from cell culture studies, in which megakaryocyte (CFU-MK) colonies form spontaneously in the absence of growth factors in the majority of patients. [4] [5] [6] [7] The basic mechanism of disease is not completely understood.
Thrombopoiesis is regulated by thrombopoietin (TPO), a growth factor whose expression responds to the number of circulating platelets. 8 Abundant platelets inhibit TPO production, whereas low platelet numbers stimulate binding of TPO to its receptor (c-MPL) in bone marrow progenitor cells. 9, 10 This ligand-receptor complex activates the tyrosine kinase JAK2, and facilitates the tyrosine phosphorylation of STAT proteins, the adaptor protein SHC and c-MPL itself. [11] [12] [13] Other growth factors, including erythropoietin, IL-11, IL-6 and stem cell factor can synergize with TPO to support megakaryocyte growth, but their independent effects are less significant and less specific. 13 Recently, our understanding of the pathophysiology of this disease has increased with the discovery of the V617F mutation in the JAK2 gene in greater than 50% of cases of ET and more than 90 and 50% of cases of the related MPDs, polycythemia vera (PV) and idiopathic myelofibrosis, respectively.
14 This finding has helped unite ET and PV with other MPD such as chronic myelogenous leukemia, systemic mastocytosis and chronic myelomonocytic leukemia through a common mechanism underlying cellular proliferation, namely that of a mutated and constitutively activated tyrosine kinase. Another mutation, W515L in the MPL gene, was recently identified in approximately 1% of ET and 4-5% idiopathic myelofibrosis (IMF) patients. Because these mutations are present in only half of cases and have been identified in several MPDs with different disease phenotypes, it is not likely to be the primary cause of ET.
Familial cases of ET provide an opportunity to identify the primary genetic defect(s) through positional cloning and mutation analysis of candidate genes. A number of kindreds have been reported with multiple people affected with a clinical presentation that ranges from a benign single lineage disease with increased megakaryopoiesis, to a multilineage condition, indistinguishable from sporadic ET. These entities have been categorized as hereditary thrombocytosis and hereditary MPD, respectively. 15 Although JAK2 mutations are commonly associated with sporadic and familial cases, germline mutations have yet to be found in familial ET. A mutation in the MPL gene that renders the receptor constitutively active has been described in one family. 16 THPO gene mutations have been identified in four other families that decreased translational repression of THPO gene expression. [17] [18] [19] [20] These families illustrate the importance of MPL gene function and translational repression of THPO gene expression in the control of thrombopoiesis and their disruption as a potential mechanism for disease.
MPL and THPO mutations account for only approximately 20% of familial cases. 15 Familial ET is heterogeneous and provides a valuable resource for studying the underlying pathobiology of ET. Here, we present laboratory investigations of such a family with multiple individuals affected with ET (and one member with PV) spanning three generations.
Materials and methods

Subjects
The family described here was initially identified by one of us (VI), who was treating two sisters with ET (individuals II-7 and II-12; Figure 1) . A three-generation pedigree was constructed with informed consent (Figure 1 ). With approval of the hospital Research Ethics Board, family members were contacted and 15 agreed to participate.
Clinical investigations, including patient chart reviews (individuals I-1, I-2, II-7, II-12 and II-14) and complete blood  counts, revealed three more family members with elevated  platelet counts (II-6, II-14 and III-6) , and two with normal platelet counts that had laboratory tests or a past medical history suggestive of hematological disease (III-7 and I-2, respectively). Diagnoses were made based on the WHO 2001 classification. 21 Peripheral blood samples were collected from participating members for cytokine (TPO and EPO) ELISA (enzyme-linked immunosorbent assay) assays, stem cell cultures assays (in heparin) and DNA extraction (in EDTA).
Measurement of TPO and EPO levels by ELISA
The Quantikine human TPO ELISA kit (R & D Systems, Minneapolis, MA, USA) was used to measure serum TPO levels. Serum EPO levels were referred out for testing to Sunnybrook Hospital in Toronto. The levels in affected and unaffected individuals were compared using the Kruskal-Wallis test.
Endogenous growth of megakaryocyte progenitor cells
A MegacultFC collagenFbased megakaryocyte progenitor detection system (Stem cell technologies, Vancouver, BC, Canada) was used to assay for spontaneous growth of patient megakaryocytes (CFU-MK). Cultures were incubated for 12 days in medium containing cytokines (TPO 50 ng/ml, rh IL-6 10 ng/ml and rh IL-3 10 ng/ml) or in medium without cytokines. Colonies containing more than 5 cells were scored microscopically. A paired Student t-test was used to compare the mean colony numbers grown with and without cytokines from different groups. Results are reported in text as mean ± s.e.m.
X-Chromosome inactivation ratios
Skewed X-chromosome inactivation (XCI) patterns are used to assess clonality of cell populations in females. For this purpose, XCI patterns were quantitated in whole blood of all affected females using PCR amplification of the HUMARA (human androgen receptor) locus, according to a protocol modified from Gale, Mien and Linch. 22 Samples were analyzed using an Applied Biosystems, Inc. (Foster City, CA, USA) 3130XL using the Fragment Analysis 36_POP7-1 run module and the Dye Set 'D'. Gene Marker (version 1.6, Soft Genetics LLC, State College PA, USA) was used to determine the areas of peaks corresponding to HUMARA alleles. The relative abundance of alleles and the XCI ratios were calculated as per Renault et al. 21 The markers ordered on chromosome 3q26-27 from top to bottom, include two proximal microsatellites (D3S2305 and D3S1617) (11.5 and 1.5 Mb, respectively), an intragenic marker (D3S4165) and three distal microsatellites (D3S1571, D3S2309 and D3S1543) (1.8, 9.7 and 11.3 Mb, respectively). Haplotypes were deduced for each individual based on segregation patterns and are depicted below the appropriate pedigree symbols. Paternally-and maternally-derived haplotypes are represented on the left and right, respectively. The original grandmaternal chromosome, which appears to segregate with the disease, has been highlighted in gray. (b) Platelet counts and serum levels of TPO and EPO. The normal range for platelet counts is 150-350 Â 10 6 /ml; for TPO concentration, 28-170 pg/ml and for EPO concentration, 5.5-33.5 U/L. Levels outside the normal range are in bold print.
Analysis of candidate genes (MPL and THPO) using linked polymorphic markers
Two restriction fragment length polymorphisms intragenic to MPL were used to follow segregation of MPL alleles through the pedigree, an AciI polymorphism within the promoter region and a DdeI polymorphism in intron 6. 24 Haplotypes of six polymorphic microsatellite marker loci in and flanking THPO were constructed for each family member and used to follow segregation of THPO alleles through the family. The DNA polymorphisms and associated PCR primers, which were selected using the Genome Data Base, (http:// gdbwww.gdb.org/) (accessed 1999) and Genbank, (http://www. ncbi.nlm.nih.gov/pubmed/) (accessed 1999) included two proximal microsatellites (D3S2305 and D3S1617), an intragenic marker (D3S4165) and three distal microsatellites (D3S1571, D3S2309 and D3S1543).
Sequencing of the THPO gene
Exons 2-7 and flanking intronic sequences of the THPO gene were amplified in 7 nested PCRs using primer sequences and PCR conditions previously described by Kondo et al. 19 An additional primer set, (F.cgaagagggggaggagagg and R.gaaggaag ggggtgagaaag), was used to amplify exon 1 and flanking intronic sequences. Amplicons were gel purified and sequenced directly.
JAK2 V617F mutation analysis DNA extracted from peripheral blood or bone marrow was amplified by a PCR according to the protocol of Baxter et al. 14 
Results
Pedigree and clinical description of affected family members
Investigation of this family began with two sisters (II-7and II-12), who were both receiving myelosuppressive (hydroxyurea) treatment for ET ( Figure 1 and Table 1 ). Both presented in early middle age and their disease has been controlled for several years. Previous clinical investigations showed increased megakaryocytes in bone marrow, normal red cell volume and no chromosome abnormalities.
Five of their seven siblings agreed to participate in these studies. Two (II-6 and II-14) were found to have elevated platelet counts. II-6 was asymptomatic. II-14 was diagnosed in early middle age with a platelet function defect following excessive postpartum bleeding, but her bleeding and easy bruising were mild and required no treatment. She had fluctuating hemoglobin levels up to 161 g/l; increased hemoglobin was considered secondary to relative polycythemia based on a red blood cell volume study. She continued to have persistent thrombocytosis.
It was not initially clear which parent carried the trait. The patriarch, I-1, was deceased, and his medical charts showed no evidence of thrombocytosis. I-2 did not have a high platelet count, but reported having had thrombotic episodes, which we concluded was probable ET.
Seven grandchildren agreed to participate in these studies. One (III-6) of the four children of affected members of the original sibship had a persistent increase in platelet counts (395 Â 10 9 /l)). Her sister (III-7) had normal platelet count, increased hemoglobin and iron deficiency. Increased red cell production in the presence of iron deficiency is suggestive of PV, another MPD, in patients with depleted iron stores from increased red cell production. 25 She subsequently had sporadic increases in platelet count. The other five grandchildren had normal platelet counts.
Cytokine assays: serum TPO and EPO levels in patients with ET and healthy controls Four of the seven affected family members had elevated TPO levels (mean ¼ 200±114 pg/ml, range: 59-263 pg/ml, n ¼ 7; Figure 1 ), whereas none of the unaffected family members had elevated TPO levels (mean ¼ 69±32 pg/ml, range: 28-124 pg/ ml, n ¼ 8). The mean TPO level for the normal unrelated controls was 108±18 pg/ml (range: 67-170 pg/ml, n ¼ 12). There was a significant difference between the TPO levels in affected and unaffected family members (Kruskal-Wallis test, P ¼ 0.008), and between affected members and normal controls (Kruskal-Wallis test, P ¼ 0.02).
Erythropoetin levels were measured in five affected and three unaffected family members, and found to be in the normal range, except for II-14, whose levels were undetectable (o5 U/ l). There was no difference between affected (mean-14.9±10.4 U/l, range:o5-32.5, n ¼ 5) and unaffected family members (mean ¼ 8.7 ± 1.5, range 7.2-10.1, n ¼ 3).
Assessment of endogenous megakaryocyte colony formation
Mononucleated cells from the peripheral blood of affected and unaffected family members were plated in culture with and without cytokines (Figure 2 ). Peripheral blood of unaffected family members and unrelated control individuals produced few megakaryocyte (CFU-MK) colonies in the absence of cytokines (1.8 ± 1.1) and numerous colonies in the presence of cytokines (21.7±10.7) (t-test, P ¼ 0.015). In contrast, megakaryocyte Table 1 Clinical features of affected and probably affected family members at presentation and at the beginning of the study, respectively Genetic analysis: candidate genes MPL, THPO and JAK2
MPL was excluded as a causative factor for familial ET in this family by the absence of genetic linkage. Haplotypes deduced from the two intragenic MPL RFLP marker loci genotypes segregated randomly with respect to the disease (data not shown) with a maximum likelihood estimate of y ¼ 0.45 (Z max ¼ 0.028).
Halotypes for each family member, deduced from genotypes at 6 polymorphic microsatellite marker loci spanning a 38-centimorgan interval containing the THPO gene, are illustrated in Figure 1 . The matriarch, I-2, was homozygous and, therefore, not informative at the THPO intrageneic marker D3S4165; however, she was heterozygous for two flanking markers, D3S1617 and D3S1571, located 1.5 Mb proximal and 1.8 Mb distal to the THPO gene, respectively. All affected individuals in the pedigree inherited the same maternal alleles at these loci and all unaffected inherited alternate alleles. Maximum likelihood estimates for recombination (y) between the disease locus and both closely-flanking marker loci was 0% (Z max ¼ 3.0). These data strongly support linkage of the disease to the THPO gene; however, sequencing of all exons and intron/ exon junctions of the THPO gene, which includes all four The 364 bp amplicon is generated from both normal and mutant alleles with primers that flank the mutation site and serves as an internal control for PCR amplification conditions. The 203 bp amplicon is generated from the mutant allele using a JAK2-allele-specific primer. previously described alleles, [17] [18] [19] [20] did not reveal a mutation in affected individual II-7.
DNA from peripheral blood was positive for the JAK2 V617F mutation in two of five affected family members (Figure 3) . EBVtransformed B-lymphocyte cell lines were available from three individuals, but no evidence of the JAK2 V617F mutation was found in DNA from these cell lines. Of particular interest are the results for patient II-7, who showed evidence of the mutation in her peripheral blood, but not in her B cells. These results show that the JAK2 V617F mutation is an acquired defect (somatic mutation), not the inherited cause of ET in this family.
Discussion
The family described here provides a rare opportunity to study the molecular basis of ET. This family demonstrates an autosomal dominant pattern of inheritance, early age of onset and variable expressivity in both the severity and the type of MPD phenotype. The characteristics of this and similar pedigrees indicate that a single genetic defect is responsible for the etiology of the familial disease; however, somatic mutations, such as the JAK2 V617F mutation, may play a role in the pathogenesis of the disease or disease progression and in the variable expressivity.
The clinical phenotype among the seven affected family members, with respect to thrombotic episodes and diagnostic features of ET (high platelet count and elevated TPO levels), was variable, as in other reports of familial ET. 26, 27 The two probands (II-7 and II-12) presented in early middle age and fulfilled the criteria for a diagnosis of sporadic ET. They required myelosuppressive treatment to control their symptoms and platelet counts. A sister (II-14) with mild symptoms and an asymptomatic brother (II-6) met the new criteria for ET of maintained platelet counts greater than 450 Â 10 9 /l. 25 The matriarch (I-2) was considered to have (probable) ET despite normal platelet counts because of reports of thrombotic episodes, high TPO levels and high endogenous CFU-MK colony growth. Two other family members with abnormal hematological test results were asymptomatic. Only four of the seven affected family members had significantly higher TPO levels than unaffected members and normal controls.
This family also displayed variable expressivity with respect to the type of MPD expressed. The clinical presentation of ET overlaps with that of another MPD, PV, but EPO levels, which are typically low in PV, could be normal in ET patients. Individuals II-7 and II-12 had EPO levels in the normal range as would be expected for patients undergoing treatment with hydroxyurea for thrombocytosis. The mildly affected and untreated sibling , in addition to meeting the laboratory criteria for ET, had fluctuating hemoglobin levels and markedly decreased EPO levels, suggestive of a mixed MPD affecting both erythroid and megakaryocyte cell lines. One of her daughters (III-7) had sporadic increases in platelet count and high endogenous CFU-MK colony growth, but her high hemoglobin levels, despite low iron stores, were judged to be more consistent with a diagnosis of PV. She and her sister (III-6) had normal TPO and EPO levels consistent with an early stage of disease. These data show that both ET and a PV-like phenotype are expressed here in the same family.
The pedigree pattern with seven affected individuals in three generations strongly indicated that a single genetic defect was responsible for disease in this family. MPL and THPO were considered prime candidate genes based on our knowledge of the biology of this disorder and on previous reports of mutation in these genes in familial ET. As a germline mutation in MPL has been ruled out in the family reported here, it seems most likely that the mutation results in either increased ligand binding to the c-MPL receptor, or alterations in signal transduction pathways activated by binding to c-MPL. A mutation in the THPO gene or in a gene regulating THPO expression, could increase activity or expression of THPO. Binding of TPO to its receptor leads to the activation of several intercellular proteins, including JAK2 and c-MPL itself, resulting in a cascade of biochemical events. 13 Mutation of a molecule involved in signal transduction may enhance the intracellular process, as is the case for the chimeric molecule BCR-ABL found in chronic myelogenous leukemia. 28 Linkage analysis provided strong evidence that the causative gene was either THPO or a closely linked gene. All four previously reported THPO mutations associated with familial ET have been located in exon 3 or intron 3, and are predicted to disrupt the ORF7 translational regulatory mechanism of TPO production. [17] [18] [19] [20] Sequencing of all THPO exons and intron/exon junctions did not identify a mutation. These results reduce the likelihood that a THPO mutation is segregating in this family; however, the strong evidence for genetic linkage and the elevated TPO levels suggest that a THPO mutation may exist in an unsequenced region at the 5 0 end of the gene, that is, the promoter/enhancer region, or introns 1 or 2. For example, such a mutation might alter binding of a trans-acting repressor of transcription or translation of THPO and increase production of TPO. Also, we cannot rule out the possibilities that the linkage detection was a false positive, that our sequencing strategy failed to detect a mutation because a PCR primer failed to hybridize with the mutant allele, or that the causative gene is a gene linked to THPO. Indeed, the haplotype segregating with disease spans a 21 Mb region estimated to contain 250 genes (www.ensembl.org) (accessed 2007), including EAP1, EVI1 and MDS1, which have been found to be involved in fusions with AML1 in acute and chronic myeloid leukemia. 29 Hematopoietic stem cells normally require a combination of cytokines such as IL-3, IL-6 and TPO to commit and proliferate into megakaryocytes whereas those from the majority of sporadic ET patients have an intrinsic property that allows for endogenous growth in the absence of cytokines. [4] [5] [6] [7] ET is generally considered a clonal stem cell disorder. 30 The family reported here had evidence of both clonal hematopoietic stem cell lineage and cytokine disorders. Some affected family members had elevated TPO (4/7), endogenous megakaryocyte colony formation (5/6) and indirect evidence of clonality (XCI studies, 6/6). We have described the disorder in this family as familial ET because it does not appear to be consistent with either hereditary MPD or hereditary thrombocytosis as defined by Kralovics and Skoda. 15 Evidence of clonal hematopoietic stem cell lineage disorder and involvement of both erythroid and megakaryocyte lineages are consistent with hereditary MPD, but elevated TPO is consistent with hereditary thrombocytosis and not with hereditary MPD.
The recent association of a specific JAK2 mutation (Val617Phe) with sporadic cases of ET, PV and IMF 14 has helped to distinguish difficult MPD diagnoses from chronic myelogenous leukemia or reactive thrombosis and has provided insight into the pathobiology of these disorders. There have been no reports of constitutional JAK2 mutations in ET families, but Rumi et al. 31 observed that in 10 of 20 familial cases studied, JAK2 mutations had been acquired by some affected individuals. Similarly, we found it in peripheral blood of two of the six affected family members tested. It is interesting that these were the two patients who required myelosuppressive therapy. In both sporadic and familial cases of ET, JAK2 mutations may not be causative, but may play an important role in disease progression. As the candidate gene approach has not been fruitful in identifying the mutation in most familial cases of ET, genome-wide scans for disease-associated loci are required. To optimize chances for success in linkage detection and fine mapping of these loci, large numbers of families with an identical condition are needed. This poses a problem in heterogeneous disorders such as familial ET. Greater statistical power may be achieved by grouping our familial ET kindred with other families in which both ET and PV occur to determine whether the disease-associated locus is in or near the THPO gene, or located elsewhere in the genome.
